vaccin
live
attenu
pathogen
virus
long
tradit
although
peopl
awar
alreadi
fifth
centuri
ad
variol
vaccin
smallpox
viru
materi
pustul
infect
peopl
practic
china
later
india
well
japan
europ
mazumdar
materi
appli
intraderm
nasal
pend
smallpox
epidem
even
grandchildren
georg
king
england
variol
rudimentari
safeti
efficaci
trial
use
deathsentenc
prison
orphan
test
although
highli
protect
variol
never
reach
gener
complianc
western
world
partli
certain
death
toll
paid
use
method
groundbreak
experi
edward
jenner
vaccin
gener
accept
jenner
prevent
smallpox
diseas
boy
preinocul
cowpox
viru
establish
convincingli
principl
immun
use
activ
agent
time
without
knowledg
natur
immunogen
immun
system
follow
discoveri
pathogen
bacteria
loui
pasteur
pioneer
develop
sever
vaccin
gener
first
live
attenu
bacteri
vaccin
extend
cultur
fowl
cholera
bacteria
could
appli
chicken
without
caus
diseas
prevent
infect
virul
strain
pasteur
discoveri
mark
start
point
develop
live
attenu
vaccin
lav
within
next
year
end
nineteenth
centuri
number
vaccin
quickli
appear
exampl
anthrax
rabi
vaccin
develop
pasteur
human
vaccin
typhoid
fever
cholera
plagu
makela
sinc
mani
lav
human
anim
use
develop
today
includ
live
attenu
bacteria
fungi
parasit
virus
vaccin
continu
tremend
impact
prevent
infecti
diseas
despit
number
vaccin
class
introduc
time
reflect
uniqu
characterist
lav
unmet
vaccin
thu
far
respect
induct
protect
immun
respons
specif
pathogen
tabl
one
hallmark
lav
effici
target
immun
induct
site
limit
infect
cycl
host
contrast
major
current
use
vaccin
preferenti
induc
antibodymedi
immun
protect
lav
capabl
stimul
cellular
immun
well
howev
potenti
risk
virul
revers
side
effect
particularli
immunocompromis
individu
led
replac
success
lav
past
rais
continu
standard
approv
new
live
vaccin
especi
human
use
tabl
anim
benefit
risk
assess
lav
often
posit
outcom
compar
small
number
approv
human
lav
oppos
rel
larg
number
veterinari
lav
whole
array
pathogen
today
advent
recombin
dna
technolog
open
possibl
target
modif
microb
pave
way
ration
attenu
lav
render
nonpathogen
even
absenc
function
host
immun
system
inert
chang
diet
commens
flora
individu
trait
addit
use
lav
deliveri
system
foreign
antigen
deriv
pathogen
therapeut
molecul
possibl
meanwhil
consider
number
recombin
lav
advanc
clinic
test
even
obtain
market
author
notabl
approv
recombin
lav
thu
far
veterinari
vaccin
meeusen
et
al
howev
rapidli
expand
knowledg
interact
recent
technolog
advanc
genom
sequenc
global
express
analysi
techniqu
well
high
end
gene
synthesi
open
complet
new
way
ration
design
lav
recombin
vaccin
deliveri
eventu
possibl
develop
new
gener
lav
tailor
specif
applic
excel
safeti
efficaci
profil
thu
har
potenti
lav
induc
arm
immun
system
vaccin
probabl
provid
new
option
fight
major
thread
human
anim
health
depend
vector
system
choic
vaccin
cargo
differ
natur
size
amount
deliv
wherea
viral
vaccin
vector
case
carri
genet
inform
foreign
antigen
order
mediat
express
host
cell
microbi
vector
system
offer
flexibl
respect
deliveri
releas
foreign
antigen
deliveri
system
design
either
directli
produc
antigen
peptid
deliv
antigenencod
nucleic
acid
host
cell
major
pathogen
bacteria
either
colon
transit
mucos
compart
infect
order
prevent
bacteri
infect
spread
diseas
induct
mucos
immun
respons
particular
import
bacteri
lav
regard
prototyp
mucos
vaccin
capabl
induc
mucos
well
system
immun
respons
dietrich
et
al
kochi
et
al
addit
mucos
vaccin
often
simplifi
administr
therebi
enhanc
safeti
reduc
cost
vaccin
origin
bacteri
lav
empir
deriv
pathogen
isol
undirect
method
passag
chemic
physic
mutagenesi
employ
order
reduc
virul
strain
yet
retain
abil
transient
colon
host
tissu
induc
protect
immun
method
stepwis
replac
sinc
direct
mutagenesi
current
three
bacteri
lav
licens
human
use
name
bacillu
calmetteguerin
bcg
salmonella
enterica
serovar
typhi
typhi
strain
vibrio
cholera
v
cholera
strain
cvd
contrast
wide
rang
bacteri
lav
util
veterinari
medicin
case
parenter
tuberculosi
tb
vaccin
bcg
passag
cultur
medium
decad
gave
rise
attenu
variant
origin
mycobacterium
bovi
isol
calmett
et
al
sinc
bcg
administ
four
billion
peopl
therefor
wide
use
bacteri
lav
human
use
thu
far
howev
bcg
alon
unabl
prevent
pulmonari
tb
adult
newborn
temporarili
protect
way
except
hivinfect
babi
mansoor
et
al
order
prevent
resurg
tb
due
reason
increas
occurr
multidrugresist
mycobacterium
tuberculosi
strain
preval
hiv
new
vaccin
urgent
need
improv
recombin
bcg
alon
part
approach
constitut
import
rout
tb
vaccin
develop
kaufmann
et
al
replac
bcg
also
tuberculosisderiv
attenu
variant
test
gonzaloasensio
et
al
veterinari
vaccin
bcg
use
success
bovin
tb
buddl
et
al
human
lav
typhoid
fever
typhi
cholera
v
cholera
cvd
oral
administ
vaccin
strain
typhi
obtain
chemic
mutagenesi
nitrosoguanidin
germani
coloni
screen
sensit
galactos
due
lack
enzym
uridin
diphosph
galactos
epimeras
gale
reason
bacteria
would
defici
polysaccharid
coat
therefor
render
vulner
immun
system
unintent
number
addit
attenu
mutat
introduc
way
germani
year
later
cholera
vaccin
strain
v
cholera
cvd
ration
deriv
pathogen
isol
genet
engin
levin
kaper
gene
ctxa
encod
toxic
subunit
cholera
toxin
delet
caus
suffici
strain
attenu
leav
express
immunogen
b
subunit
unaffect
furthermor
gene
hlya
encod
hemolysin
disrupt
integr
mercuri
resist
gene
allow
discrimin
wildtyp
strain
veterinari
medicin
sinc
decad
mani
lav
bacteri
diseas
use
establish
case
undirect
mutagenesi
promin
exampl
vaccin
salmonellosi
poultri
swine
cattl
variou
serovar
salmonella
enterica
caus
agent
either
enter
septicemia
anim
turn
contamin
animalderiv
food
product
main
sourc
human
salmonella
infect
barrow
attenu
salmonella
vaccin
strain
establish
chemic
mutagenesi
introduc
veterinari
practic
often
use
today
lind
et
al
meyer
et
al
direct
attenu
genet
engin
becam
feasibl
number
suitabl
gene
target
identifi
belong
mainli
metabol
pathway
regulatori
system
virul
determin
interfer
synthesi
aromat
amino
acid
delet
gene
aroa
encod
synthas
prove
excel
strategi
safe
attenu
retain
immunogen
typhimurium
strain
hoiseth
stocker
concept
subsequ
transfer
attenu
number
bacteria
aeromona
salmonicida
vaughan
et
al
yersinia
enterocolitica
bow
et
al
pasteurella
multocida
homchampa
et
al
escherichia
coli
fan
et
al
streptococcu
equi
jacob
et
al
sever
strain
success
commerci
lav
anim
use
strategi
reduc
likelihood
virul
revers
eg
due
unwant
acquisit
complement
dna
sequenc
attenu
multipl
gene
propos
mutat
gene
aroa
arod
part
metabol
pathway
introduc
vaccin
strain
typhi
chatfield
et
al
shigella
flexneri
verma
lindberg
prerequisit
use
anim
vaccin
often
abil
differenti
infect
vaccin
anim
diva
concept
van
oirschot
achiev
delet
immunogen
antigen
vaccin
anim
seroneg
protect
vaccin
antigen
case
actinobacillu
pleuropneumonia
caus
agent
porcin
pleuropneumonia
sequenti
delet
six
gene
gave
rise
appropri
attenu
candid
vaccin
strain
also
compli
diva
concept
maa
et
al
howev
remov
virul
determin
often
give
rise
strain
fail
transient
colon
immun
induct
site
therefor
induc
potent
immun
respons
accord
socal
strategi
regul
delay
attenu
establish
recent
order
circumv
problem
curtiss
iii
et
al
vaccin
strain
design
way
invas
phenotyp
strain
retain
initi
phase
vaccin
immun
induct
site
colon
subsequ
due
lack
particular
substrat
vivo
invas
phenotyp
bacteria
fade
acut
diseas
elicit
proof
concept
establish
mutant
strain
lack
either
gene
gale
pmi
phosphomannos
isomeras
curtiss
iii
et
al
mutant
attenu
due
lack
function
lipopolysaccharid
lp
howev
grown
presenc
either
galactos
mannos
respect
mutant
synthes
lp
abl
colon
host
tissu
upon
oral
administr
sinc
sugar
present
vivo
lp
synthesi
subsequ
abrog
bacteria
render
vulner
host
defens
final
success
establish
clinic
test
bacteri
lav
care
risk
assess
necessari
prior
vaccin
registr
frey
despit
safeti
concern
approv
genet
modifi
lav
present
ration
engin
strain
probabl
gain
accept
futur
due
high
degre
molecular
definit
addit
superior
perform
induct
strong
antibodi
respons
high
amount
antigen
requir
case
wherea
cellular
respons
moder
antigen
deliveri
may
suffic
therefor
strong
constitut
promot
use
initi
express
heterolog
antigen
bacteri
lav
brown
et
al
howev
even
achiev
highlevel
express
antigen
often
constitut
seriou
burden
vaccin
strain
reduc
abil
tissu
colon
induc
immun
respons
solut
problem
use
vivo
induc
ivi
promot
propos
deriv
gene
becom
activ
condit
encount
certain
stage
colon
cours
first
nitrit
reductas
promot
pnirb
e
coli
employ
induc
intestin
hypoxia
chatfield
et
al
subsequ
number
addit
ivi
promot
test
express
heterolog
antigen
hohmann
et
al
stratford
et
al
valdivia
falkow
individu
promot
differ
time
level
antigen
express
consequ
influenc
antigenspecif
immun
induct
bumann
altern
approach
develop
curtiss
lab
name
regul
delay
synthesi
antigen
xin
et
al
antigen
product
retard
due
arabinosedepend
express
repressor
protein
driven
pbad
promot
vitro
guzman
et
al
upon
vaccin
administr
repressor
express
ceas
due
lack
arabinos
gastrointestin
tract
mice
thu
reliev
repressor
blockad
antigen
express
cassett
strategi
use
ivi
promot
employ
regul
delay
synthesi
system
time
point
antigen
synthesi
express
level
fix
tune
vaccin
therefor
recent
test
suitabl
substrateinduc
promot
deliber
onset
adjust
report
gene
express
bacteri
lav
vivo
loessner
et
al
promot
constitut
new
option
induc
antigen
express
control
manner
vivo
concept
term
vivo
remot
control
ivrc
howev
sinc
optim
induct
immun
respons
respons
continu
antigen
express
necessari
griffin
mcsorley
prolong
administr
induc
substrat
would
probabl
requir
ivrc
promot
employ
plasmid
harbor
express
cassett
often
use
convers
vaccin
strain
deliveri
vehicl
heterolog
antigen
main
advantag
plasmid
easili
manipul
e
coli
subsequ
transfer
vaccin
strain
addit
multicopi
plasmid
mediat
elev
level
antigen
synthesi
comparison
singlecopi
chromosom
express
cassett
howev
episom
plasmid
replic
constitut
metabol
burden
bacteria
thu
attenu
vaccin
strain
covon
et
al
moreov
plasmid
mainten
often
achiev
antibiot
select
vitro
absenc
select
pressur
vivo
plasmid
often
lost
prolifer
bacteria
order
ensur
stabil
plasmid
transform
without
need
antibiot
select
socal
balanc
lethal
system
establish
curtiss
iii
et
al
system
reli
host
strain
chromosom
delet
essenti
metabol
gene
defect
gene
complement
express
plasmid
therefor
ensur
stabl
plasmid
propag
altern
approach
use
socal
addict
system
plasmid
stabil
galen
et
al
contrast
integr
express
cassett
bacteri
genom
ensur
stabl
propag
howev
genom
integr
singl
express
cassett
often
mediat
synthesi
suffici
antigen
level
solut
problem
would
multipl
integr
express
cassett
howev
recombin
compet
vaccin
strain
repetit
homolog
sequenc
often
instabl
due
undesir
recombin
event
accord
remov
recombinas
vaccin
strain
import
advanc
stabil
repetit
chromosom
integr
also
plasmid
dna
zhang
et
al
nowaday
gene
synthesi
rapidli
replac
clone
procedur
establish
antigen
express
cassett
kindsmul
wagner
thu
fine
tune
promot
element
optim
code
sequenc
eg
adjust
codon
usag
acceler
tremend
sever
properti
vaccin
strain
cellular
tropism
bacteri
virul
mechan
type
attenu
predetermin
time
point
locat
antigen
deliveri
fig
cheminay
hensel
loessner
et
al
sinc
requir
protect
immun
respons
pathogen
differ
target
heterolog
antigen
differ
present
pathway
necessari
thu
choic
right
attenu
vaccin
strain
import
accomplish
effici
target
heterolog
antigen
synthes
bacteri
lav
releas
bacteria
order
recogn
immun
cell
gramneg
bacteria
lack
gene
asd
encod
aspartatesemialdehyd
dehydrogenas
undergo
cell
death
environ
lack
diaminopimel
acid
dap
sinc
dap
absent
gastrointestin
tract
oral
appli
bacteria
defici
asd
quickli
lyse
vivo
curtiss
iii
dapless
death
bacteri
cell
wall
spontan
burst
cytoplasm
cellular
content
protein
nucleic
acid
effici
releas
loessner
et
al
contrast
lethal
attenu
defici
thya
thymidyl
synthas
thymin
thymidinedepriv
environ
caus
ruptur
bacteri
cell
therefor
immedi
releas
cytoplasm
materi
occur
henc
subsequ
slow
degrad
bacteri
carcass
may
prevent
releas
present
heterolog
antigen
altern
strain
attenu
induc
lysi
system
develop
mediat
effici
releas
cytoplasm
antigen
nucleic
acid
ruptur
bacteri
cell
instanc
bacteriophag
lysi
determin
employ
purpos
jain
mekalano
use
lysi
protein
e
deriv
phage
alreadi
employ
time
prepar
bacteri
cell
envelop
devoid
cytoplasm
content
use
vaccin
socal
bacteri
ghost
jalava
et
al
employ
lysi
determin
releas
heterolog
antigen
bacteri
vector
strain
necessit
tightli
regul
induc
express
vivo
achiev
link
lysi
gene
e
arabinoseinduc
pbad
promot
suitabl
ivrc
see
loessner
et
al
recent
quorum
sens
ironregul
promot
guan
et
al
silva
et
al
similar
dapless
death
lysi
protein
e
caus
ruptur
bacteri
cell
interfer
cell
wall
synthesi
bernhardt
et
al
anoth
lysi
strategi
establish
curtiss
lab
term
regul
delay
lysi
system
kong
et
al
work
salmonella
doubl
mutant
strain
construct
chromosom
delet
two
gene
involv
cell
wall
biosynthesi
asd
mura
plasmidencod
complement
gene
link
arabinoseinduc
pbad
promot
kept
activ
presenc
arabinos
cultur
upon
oral
vaccin
administr
express
gene
ceas
due
absenc
arabinos
vivo
bacteria
disintegr
thu
system
confer
attenu
mediat
antigen
releas
time
wherea
cytoplasm
antigen
releas
bacteria
undergo
lysi
viabl
bacteri
carrier
engin
releas
antigen
continu
use
suitabl
secret
system
varieti
onecompon
multicompon
secret
system
employ
task
singlecompon
system
socal
autotransport
e
coli
aidai
maurer
et
al
suitabl
transloc
passeng
antigen
across
gramneg
cell
envelop
stabl
display
antigen
surfac
salmonella
vaccin
strain
via
e
coli
aidai
effici
induc
cellular
immun
reaction
kramer
et
al
similarli
e
coli
alphahemolysin
hlya
secret
apparatu
belong
group
type
secret
system
fulli
activ
salmonella
vaccin
strain
success
use
deliveri
number
antigen
gentschev
et
al
system
compos
three
protein
mediat
transloc
passeng
antigen
fuse
hlya
signal
peptid
directli
extracellular
medium
socal
type
iii
secret
system
use
bacteri
pathogen
deliveri
virul
factor
across
eukaryot
membran
hueck
complex
easili
transfer
one
bacteri
vector
anoth
howev
natur
harbor
vaccin
strain
effici
subvert
deliveri
antigen
directli
cytosol
host
cell
russmann
et
al
way
antigen
target
mhci
present
pathway
extracellular
phagosomerestrict
bacteri
vector
russmann
et
al
panthel
et
al
nevertheless
specif
particular
virul
factor
render
system
difficult
gener
applic
antigen
secret
gramneg
bacteri
vaccin
strain
contrast
secret
system
gramposit
bacteria
often
less
restrict
particular
virul
factor
might
allow
continu
secret
antigen
vaccin
carrier
buist
et
al
alreadi
time
ago
capabl
bacteria
deliv
nucleic
acid
mammalian
cell
discov
schaffner
meanwhil
bacteriamedi
transfer
plasmid
dna
encod
vaccin
antigen
therapeut
molecul
demonstr
experiment
anim
model
infecti
diseas
tumor
gene
defici
becker
et
al
daudel
et
al
loessner
weiss
bacteria
compet
access
host
cell
cytoplasm
observ
display
highest
transfer
effici
nucleic
acid
courvalin
et
al
dietrich
et
al
sizemor
et
al
howev
bacteria
restrict
intracellular
vacuolar
compart
salmonella
also
capabl
mediat
dna
transfer
certain
extent
unknown
mechan
darji
et
al
use
typhimurium
strain
lack
ssrab
two
essenti
gene
mainten
phagosom
integr
intracellular
growth
improv
dna
deliveri
capac
vaccin
strain
bai
et
al
addit
extracellular
bacteria
mediat
dna
deliveri
mammalian
cell
conjug
apparatu
kunik
et
al
water
comparison
dna
deliveri
system
bacteri
vector
nearli
unlimit
capac
regard
size
instanc
infecti
viru
could
reconstitut
deliveri
complet
genom
murin
cytomegaloviru
mcmv
salmonella
vaccin
strain
mammalian
cell
cicinsain
et
al
specif
silenc
mammalian
gene
achiev
engin
e
coli
strain
could
mediat
deliveri
short
hairpin
rna
shrna
xiang
et
al
howev
sever
bottleneck
identifi
counteract
bacteri
deliveri
nucleic
acid
mammalian
cell
cellular
defens
mechan
autophagi
ogawa
et
al
bacteriainduc
cellular
activ
cell
death
fink
cookson
factor
restrict
transfer
effici
nevertheless
bacteriamedi
gene
transfer
remain
attract
altern
antigen
deliveri
sinc
antigen
produc
eukaryot
cell
obstacl
like
ineffici
protein
fold
posttransl
modif
secret
circumv
addit
bacteria
repres
power
adjuv
help
trigger
efficaci
immun
respons
best
exampl
success
bacteriamedi
dna
vaccin
experi
reisfeld
group
use
oral
salmonella
vector
deliveri
anticanc
vaccin
reisfeld
et
al
vaccinemedi
restrict
tumor
angiogenesi
one
approach
work
one
target
use
vascular
endotheli
growth
factor
receptor
also
refer
molecul
express
tumor
cell
highli
express
endotheli
cell
grow
tumor
capillari
eukaryot
express
plasmid
transfer
oral
salmonella
mice
anim
protect
subsequ
challeng
differ
tumor
colon
carcinoma
niethamm
et
al
even
month
vaccin
anim
could
resist
challeng
also
use
socal
minigen
express
epitop
success
restrict
tumor
growth
due
tcell
respons
luo
et
al
advantag
minim
code
sequenc
probabl
mutat
reduc
antigen
deliveri
bacteria
facilit
anoth
possibl
strategi
use
dna
vaccin
coexpress
cytokin
chemokin
conjunct
antigen
multifunct
cytokin
abl
improv
tumor
antigen
present
dc
coexpress
tumor
antigen
fosrel
antigen
overexpress
mani
epitheli
carcinoma
togeth
mediat
reduct
metastas
luo
et
al
anoth
approach
inhibit
angiogenesi
achiev
salmonellamedi
oral
deliveri
apoptosi
protein
survivin
chemokin
parallel
attract
activ
dc
cell
tumor
site
vaccin
prevent
pulmonari
tumor
growth
metastas
reduc
growth
alreadi
establish
tumor
xiang
et
al
express
fibroblast
activ
protein
fap
determin
approxim
human
epitheli
tumor
specif
stromal
fibroblast
solid
tumor
salmonellamedi
deliveri
dna
vaccin
fap
enhanc
efficaci
doxorubicin
chemotherapi
suppress
spontan
metastas
addit
combin
therapi
inhibit
tumor
angiogenesi
reduc
express
prolif
factor
tumor
microenviron
liao
et
al
attenu
strain
gramposit
bacteria
l
monocytogen
also
studi
context
tumor
vaccin
bacteria
abl
infect
phagocyt
nonphagocyt
cell
spread
bodi
without
attack
antibodi
respons
l
monocytogen
infect
stimul
strong
innat
adapt
immun
respons
render
effici
vaccin
vector
candid
barbuddh
chakraborti
addit
cytosol
intracellular
resid
bacteria
favor
tcell
respons
necessari
gener
antitumor
immun
ensur
bacteri
secret
specif
antigen
case
antigen
fuse
secretori
bacteri
protein
llo
one
exampl
l
monocytogen
tumor
vaccin
strain
produc
human
papillomaviru
hpv
antigen
associ
cervix
head
neck
cancer
gunn
et
al
anim
vaccin
induc
immun
respons
caus
regress
tumor
express
phase
clinic
trial
vaccin
demonstr
safe
human
maciag
et
al
patient
five
progress
seven
stabl
diseas
one
qualifi
partial
respond
increas
surviv
patient
observ
day
three
patient
still
aliv
year
treatment
l
monocytogen
also
employ
deliveri
prostat
cancer
vaccin
l
monocytogen
engin
deliv
fusion
protein
mous
model
demonstr
vaccin
immunogen
caus
regress
establish
psaexpress
tumor
shahabi
et
al
apart
power
carrier
novel
vaccin
strategi
particular
bacteria
show
also
potenti
use
cancer
therapi
due
abil
target
colon
tumor
upon
system
administr
leschner
weiss
among
bacteria
abl
target
tumor
anaerob
like
clostridia
bifidobacteria
well
facult
anaerob
like
salmonella
e
coli
interestingli
alreadi
nineteenth
centuri
sever
physician
observ
cancer
patient
caught
infect
sometim
cure
tumor
coley
even
intent
infect
cancer
patient
mediat
success
tumor
cure
case
howev
patient
infect
fatal
therefor
approach
abandon
time
today
new
option
attenu
program
bacteria
develop
cancer
therapeut
base
live
bacteria
becom
feasibl
sinc
bacteri
strain
use
cancer
therapi
pathogen
first
attenu
strain
investig
test
alreadi
vaccin
carrier
like
leschner
et
al
westphal
et
al
yu
et
al
alramadi
et
al
yoon
et
al
avogadri
et
al
yang
et
al
strain
defici
synthesi
aromat
amino
acid
besid
also
strain
attenu
especi
tumortarget
purpos
one
exampl
salmonella
strain
render
auxotroph
leucin
arginin
reisol
tumor
enhanc
tumor
specif
colon
variou
human
tumor
metastas
nude
mice
clear
rapidli
organ
hayashi
et
al
hayashi
et
al
kimura
et
al
nagakura
et
al
zhao
et
al
anoth
salmonella
strain
consid
display
improv
safeti
profil
produc
modifi
lipopolysaccharid
thu
induc
dramat
diminish
level
human
peripher
leukocyt
low
et
al
unfortun
readili
colon
tumor
patient
phase
trial
heimann
rosenberg
toso
et
al
possibl
strain
overattenu
sinc
shown
play
import
role
invas
process
salmonella
tumor
leschner
et
al
thu
present
major
challeng
develop
tumortarget
bacteria
proper
attenu
strain
without
restrict
capabl
colon
tumor
tissu
apart
inher
antitumor
effect
bacteria
could
use
carrier
deliv
therapeut
agent
directli
cancer
tissu
differ
class
molecul
test
one
class
repres
immun
modulatori
molecul
enhanc
immun
respons
toward
tumor
directli
kill
cancer
cell
light
fa
ligand
test
context
alramadi
et
al
alramadi
et
al
loeffler
et
al
loeffler
et
al
b
saltzman
et
al
sorenson
et
al
b
toxic
agent
anoth
possibl
enhanc
anticanc
effect
bacteria
instanc
bacteri
toxin
cytolysin
result
strong
reduct
tumor
growth
express
tumorcolon
typhimurium
nguyen
et
al
ryan
et
al
third
class
molecul
socal
prodrugconvert
enzym
convert
nontox
prodrug
toxic
substanc
exampl
thymidin
kinas
herp
simplex
viru
e
coli
cytosin
deaminas
use
context
king
et
al
nemuna
et
al
pawelek
et
al
royo
et
al
tumor
therapeut
bacteria
mediat
deliveri
eukaryot
express
plasmid
therapeut
factor
interf
rna
speci
also
develop
tumor
therapeut
approach
use
protein
like
endostatin
fmslike
tyrosin
kinas
ligand
also
e
coli
prodrugconvert
enzym
purin
nucleosid
phosphorylas
apoptosisinduc
protein
trail
smac
led
effici
treatment
variou
tumor
mice
fu
et
al
b
c
lee
et
al
yoon
et
al
similarli
sirna
eukaryot
plasmid
target
antiapoptot
protein
show
potenti
use
treatment
tumor
although
promis
mechan
lead
effect
unclear
salmonella
rare
found
insid
tumor
cell
host
cell
agorio
et
al
loessner
weiss
pawelek
et
al
therefor
question
cell
target
gene
transfer
still
answer
construct
efficaci
anticanc
bacterium
regul
therapeut
molecul
express
crucial
use
particular
promot
allow
predetermin
exact
onset
therapeut
treatment
well
termin
eg
via
express
suicid
gene
loessner
et
al
therefor
induc
promot
like
pbad
promot
mention
enabl
start
express
upon
administr
induc
substanc
desir
time
point
loessner
et
al
furthermor
tumorspecif
promot
exclus
drive
protein
express
insid
neoplasia
tissu
host
import
aspect
avoid
side
effect
healthi
organ
arrach
et
al
leschner
et
al
bacteriamedi
tumor
therapi
often
met
skeptic
despit
undisput
success
experiment
preclin
model
although
still
requir
mani
iter
step
convert
gener
applic
therapeut
strategi
undoubtedli
great
potenti
certain
tumor
human
patient
colon
bacteria
demonstr
futur
implement
therapeut
option
realist
almost
human
veterinari
vaccin
viral
diseas
use
today
live
attenu
inactiv
viru
vaccin
live
viru
vaccin
either
deriv
relat
low
pathogen
virus
enabl
crossprotect
highli
pathogen
viru
strain
like
cowpox
vaccinia
viru
vaccin
variola
viru
caus
smallpox
deriv
undirect
attenu
virus
sinc
develop
time
knowledg
viru
genom
mechan
virul
still
lack
mutagenesi
virus
rel
random
past
attenu
viru
achiev
passag
embryon
egg
anim
differ
vertebr
speci
follow
cell
cultur
adapt
later
establish
standard
cell
cultur
techniqu
live
viru
vaccin
propag
primari
cell
like
chicken
embryon
fibroblast
human
diploid
cell
line
eg
definit
life
span
facilit
process
vaccin
product
cell
success
replac
continu
cell
line
ccl
due
improv
character
cell
widen
analyt
technolog
abl
determin
possibl
oncogen
potenti
thu
far
small
number
human
vaccin
produc
ccl
gregersen
et
al
african
green
monkey
kidney
cell
line
vero
wide
accept
ccl
regulatori
author
use
year
product
polio
rabi
viru
vaccin
barrett
et
al
furthermor
vaccin
manufactur
season
pandem
influenza
vaccin
variou
stage
develop
cellderiv
vaccin
pandey
et
al
vero
cell
madindarbi
canin
kidney
mdck
cell
often
ccl
choic
govorkova
et
al
hu
et
al
current
live
viral
vaccin
attenu
strain
polioviru
well
measl
mump
rubella
viru
countri
latter
given
tripl
vaccin
call
mmr
vaccin
vaccin
appli
success
brought
world
closer
toward
erad
addit
viral
diseas
besid
smallpox
thu
far
polio
elimin
part
world
european
countri
claim
erad
measl
viru
achiev
possibl
virus
restrict
human
host
persist
anim
reservoir
addit
one
viral
serotyp
variola
mump
measl
rubella
serotyp
polio
exist
thu
possibl
induc
protect
antibodi
titer
rel
simpl
vaccin
composit
tcell
immun
known
play
role
induct
protect
immun
measl
viru
griffin
pan
role
cell
immun
virus
still
clear
unfortun
countri
still
remain
endem
measl
viru
due
variou
factor
polit
problem
inappropri
health
care
system
socioeth
reason
inher
biolog
characterist
viru
chumakov
et
al
howev
also
industri
countri
complianc
routin
vaccin
children
ceas
extent
henc
effort
polit
health
care
profession
one
hand
also
develop
new
vaccin
necessari
order
achiev
goal
global
erad
virus
exampl
research
measl
vaccin
includ
also
develop
dna
vaccin
subunit
vaccin
virusvector
vaccin
griffin
pan
furthermor
develop
robust
vaccin
simpl
applic
procedur
great
import
regard
develop
thermost
vaccin
vaccin
needlefre
applic
eg
aerosol
administr
progress
higginson
et
al
moreov
safeti
measl
vaccin
hivinfect
person
improv
strebel
et
al
erad
polioviru
almost
achiev
use
trival
polio
vaccin
howev
monoval
oral
polio
vaccin
opv
inactiv
polio
vaccin
ipv
shall
enabl
complet
erad
polio
ehrenfeld
et
al
mani
live
vaccin
use
livestock
like
bovin
respiratori
syncyti
viru
cattl
caliciviru
cat
thu
far
success
live
viral
vaccin
rinderpest
vaccin
succeed
complet
erad
diseas
use
inactiv
viru
vaccin
altern
applic
viral
lav
one
advantag
pathogen
viral
isol
use
today
inactiv
vaccin
produc
tickborn
enceph
viru
hepat
viru
season
influenza
japanes
enceph
viru
rabi
yellow
fever
spectrum
veterinari
viral
diseas
inactiv
vaccin
advantag
increas
safeti
sinc
abl
replic
cell
vaccin
host
therefor
spread
contact
howev
due
replic
defici
vaccin
stimul
mainli
antibodi
respons
moreov
inactiv
process
eg
action
formaldehyd
antigen
vaccin
might
reduc
due
destruct
protect
epitop
fraenkelconrat
mecham
metz
et
al
thu
inactiv
virus
often
reach
efficaci
live
attenu
viru
protect
immun
respons
alway
elicit
fig
efficaci
obtain
live
viru
vaccin
case
prevent
develop
inactiv
vaccin
howev
use
adjuv
altern
inactiv
procedur
vaccin
composit
may
allow
gener
new
inactiv
vaccin
increas
efficaci
abl
induc
antibodi
well
tcellmedi
immun
respons
amanna
slifka
nevertheless
despit
improv
safeti
requir
research
live
attenu
virus
also
maintain
instanc
coldadapt
season
influenza
vaccin
recent
approv
usa
kreijtz
et
al
recombin
biotechnolog
allow
develop
two
success
viral
subunit
vaccin
human
hepat
b
viru
hbv
human
papillomaviru
hpv
hbv
vaccin
regist
highli
protect
reduc
endem
area
dramat
hepatocellular
carcinoma
sequel
chronic
hbv
infect
hbv
vaccin
produc
yeast
mammalian
cho
cell
consist
recombin
surfac
protein
viru
hbsag
mcaleer
et
al
two
major
yeastderiv
hepat
b
vaccin
licens
countri
given
monoval
vaccin
howev
formul
hepat
vaccin
also
avail
previsani
lavanchi
hpv
vaccin
direct
virusinduc
cervic
cancer
vulvar
vagin
cancer
genit
wart
young
women
men
two
prophylact
hpv
vaccin
approv
europ
usa
target
hpv
serotyp
addit
consist
yeast
insect
cellproduc
shell
protein
selfassembl
viruslik
particl
glaxosmithklin
merck
co
public
vaccin
campaign
smallpox
sever
side
effect
toler
side
effect
includ
gener
vaccinia
unwant
spread
unprotect
contact
person
even
lifethreaten
reaction
like
eczema
vaccinatum
vaccinia
necrosum
postvaccin
enceph
howev
despit
sporad
occurr
zoonot
poxviru
infect
threat
bioterror
today
side
effect
nowaday
intoler
therefor
besid
continu
use
vaccinia
viru
vacv
vaccin
dryvax
certain
person
group
usa
attenu
strain
develop
modifi
vaccinia
viru
ankara
mva
deriv
chorioallantoi
viru
strain
ankara
mayr
et
al
new
york
vacv
nyvac
base
copenhagen
strain
vacv
tartaglia
et
al
deriv
vacv
lister
strain
kenner
et
al
like
convent
vacv
mva
nyvac
potent
induc
humor
cellular
immun
respons
howev
vaccin
consider
differ
immunestimul
capac
mva
gener
passag
viru
time
chicken
embryon
fibroblast
wherebi
gain
mani
delet
point
mutat
result
loss
kb
dna
comparison
parent
strain
contrast
nyvac
receiv
delet
particular
gene
virus
function
sever
immun
suppress
gene
lost
result
genet
divers
mva
nyvac
differenti
stimul
immun
respons
host
exampl
distinct
gene
express
profil
induc
upon
infect
human
monocytederiv
dendrit
cell
guerra
et
al
najera
et
al
moreov
parallel
comparison
vector
determin
vaccin
efficaci
macaqu
hiv
model
show
tcelldriven
immun
respons
nyvac
wherea
mva
induc
well
tcell
respons
heterolog
vaccin
antigen
mooij
et
al
molecular
immunolog
basi
innat
adapt
immun
stimul
virus
intens
investig
interestingli
mva
uniqu
abil
induc
type
interferon
spectrum
chemokin
cytokin
contrast
vacv
guerra
et
al
lehmann
et
al
waibler
et
al
due
genom
delet
mva
nyvac
lost
capac
replic
mammalian
cell
consequ
spread
vivo
drexler
et
al
gomez
et
al
meyer
et
al
tartaglia
et
al
virus
test
sever
anim
model
found
highli
attenu
comparison
vacv
moreov
mva
alreadi
use
human
proven
exhibit
excel
safeti
profil
appli
human
includ
highrisk
patient
still
poxviru
erad
program
mayr
et
al
later
sever
phase
clinic
trial
differ
mva
vector
vaccin
administ
high
dose
confirm
safeti
profil
mva
goepfert
et
al
von
krempelhub
et
al
wilck
et
al
comparison
viral
vector
note
mva
nyvac
like
poxvirus
replic
exclus
cytoplasm
infect
cell
make
gene
transfer
event
host
cell
genom
unlik
despit
lack
product
infect
mva
nyvac
exert
full
gene
express
profil
suitabl
mediat
highlevel
product
recombin
antigen
sutter
moss
tartaglia
et
al
welldefin
protocol
gener
recombin
virus
establish
use
homolog
recombin
technolog
plaqu
select
help
differ
marker
gene
carrol
moss
staib
et
al
recent
recombin
vacv
mva
vaccin
gener
use
bacteri
artifici
chromosom
simplifi
construct
vector
vaccin
cottingham
et
al
domi
moss
virus
toler
larg
insert
foreign
sequenc
doublestrand
dna
genom
normal
stabl
mva
produc
larg
amount
even
use
dri
vaccin
thu
suitabl
also
applic
area
cool
chain
guarante
addit
mucos
needlefre
applic
freezedri
mva
mice
clearli
demonstr
potenc
formul
induc
immun
respons
compar
parenter
applic
protect
lethal
bacteri
viral
challeng
gener
way
kastenmul
et
al
featur
proof
recombin
mva
vacv
simpl
safe
vaccin
platform
gener
applic
mva
nyvac
develop
vector
vaccin
divers
set
infect
cancer
allerg
diseas
besid
use
mva
directli
poxviru
vaccin
mvabas
vector
vaccin
hiv
malaria
differ
cancer
allergi
investig
preclin
also
clinic
phase
andor
ii
trial
albrecht
et
al
gomez
et
al
canarypox
fowlpox
avipoxvirus
use
sinc
time
vector
vaccin
avipoxvirus
strict
host
tropism
bird
contain
abil
infect
mammalian
cell
strongli
express
heterolog
antigen
without
complet
viru
life
cycl
constitut
import
safeti
featur
live
attenu
viru
vector
canarypox
shown
elicit
humor
cellular
immun
respons
vaccin
subject
zanotto
et
al
interestingli
recombin
canarypox
found
abl
induc
stronger
protect
immun
respons
compar
similar
fowlpox
vaccin
taylor
et
al
today
sever
canarypoxbas
veterinari
vaccin
routin
use
poulet
et
al
base
alvac
strain
plaqu
isol
canari
vaccin
kanapox
human
alvacbas
hiv
vaccin
alvachiv
express
glycoprotein
clade
current
test
phase
iii
clinic
trial
rerksngarm
et
al
contrast
trial
recombin
vaccin
given
alon
regimen
togeth
recombin
hiv
glycoprotein
subunit
vaccin
aidsvax
gave
encourag
result
efficaci
trial
perform
thailand
hiv
acquisit
significantli
reduc
vaccin
group
vaccari
et
al
measl
viru
also
known
rubeola
morbilli
envelop
singlestrand
negativesens
rna
viru
infect
respiratori
system
belong
famili
paramyxovirida
genu
morbilliviru
develop
countri
children
immun
measl
howev
worldwid
approxim
children
die
measl
year
immun
respons
induc
routin
vaccin
repres
problem
use
recombin
measl
vector
vaccin
hand
extens
clinic
experi
adapt
measl
vaccin
rare
side
effect
capac
induc
strong
often
lifelong
immun
render
measl
viru
highli
suitabl
vaccin
vector
use
nonseg
negativestrand
rna
viru
mononegaviral
vector
possibl
nowaday
stateoftheart
molecular
method
produc
cdna
clone
technolog
allow
sitedirect
mutagenesi
studi
gene
function
well
insert
foreign
code
sequenc
develop
multival
vaccin
measl
pathogen
use
measl
viru
vector
experiment
promot
high
genet
stabil
unexpect
rna
virus
accept
foreign
sequenc
quit
possibl
convert
measl
viru
vaccin
vector
meantim
appropri
replicon
helper
cell
helper
virus
construct
collin
et
al
conzelmann
schnell
martin
et
al
schneider
et
al
sidhu
et
al
takeda
et
al
newli
develop
system
allow
insert
addit
transcript
unit
heterolog
antigen
maxim
insert
capac
toler
viru
kb
express
level
insert
gene
depend
posit
within
viral
genom
billet
et
al
hangartn
singh
et
al
wang
et
al
zuniga
et
al
measlesbas
vector
vaccin
consid
candid
multival
vector
vaccin
express
antigen
hepat
b
del
vall
et
al
singh
et
al
sivhiv
brandler
tangi
lorin
et
al
tangi
naim
wang
et
al
zuniga
et
al
west
nile
dengu
viru
brandler
tangi
despr
et
al
sar
coronaviru
linig
et
al
sever
studi
mous
model
shown
recombin
measl
vaccin
capabl
induc
humor
immun
measl
heterolog
antigen
de
vri
et
al
first
candid
vaccin
hivmeasl
develop
last
year
tangi
group
pasteur
institut
enter
soon
clinic
test
phase
yellow
fever
acut
viral
hemorrhag
diseas
caus
envelop
singlestrand
positivesens
rna
viru
flavivirida
famili
surviv
infect
yellow
fever
viru
result
lifelong
immun
normal
perman
organ
damag
encount
individu
schmaljohn
mcclain
origin
yellow
fever
vaccin
live
attenu
viru
base
yellow
fever
viru
strain
develop
almost
year
ago
empir
method
still
consid
one
safest
effect
viru
vaccin
start
vaccin
live
attenu
chimer
virus
construct
replac
gene
code
premembran
prm
envelop
e
protein
vaccin
strain
heterolog
flavivirus
chimerivax
technolog
gene
japanes
enceph
viru
je
encod
je
protein
draper
heeney
latter
chimera
complet
phase
iii
trial
current
preregistr
je
vaccin
previous
known
chimerivaxjetm
suppos
becom
first
approv
human
viral
vector
vaccin
appaiahgari
vrati
human
adenovirus
belong
famili
adenovirida
virus
famili
infect
human
anim
adenovirus
nonenvelop
icosahedr
virus
assembl
nucleocapsid
harbor
doublestrand
linear
dna
genom
serotyp
adenovirus
human
variabl
morpholog
kaufman
viru
respons
ocular
respiratori
gastrointestin
epithelium
infect
children
also
adult
alreadi
cell
line
establish
enabl
product
recombin
adenovirus
helperfre
environ
sinc
landmark
adenovir
vector
receiv
attent
gene
transfer
agent
gene
therapi
vectorbas
vaccin
randrianarisonjewtoukoff
perricaudet
attenu
usual
achiev
delet
gene
known
essenti
adenovir
replic
carlock
jone
gaynor
berk
vector
abl
infect
cell
without
caus
cellular
damag
first
vector
gener
delet
region
essenti
vitro
vector
product
adenoviru
vector
abl
deliv
gene
nearli
effici
wide
rang
cell
type
includ
divid
nondivid
cell
well
primari
cell
possibl
produc
extrem
high
viral
titer
adenovir
vector
provid
capac
kb
foreign
recombin
gene
classic
adenoviru
vector
gener
recombin
gene
insert
delet
region
viral
cdna
vitro
ligat
homolog
recombin
protocol
wolff
lederberg
new
approach
allow
gener
recombin
adenovirus
transposit
e
coli
richard
et
al
viral
product
normal
modifi
cell
util
cell
stabli
transfect
region
adenovir
genom
allow
vector
replic
matur
result
vector
particl
prepar
cell
line
lack
region
remain
replic
defici
viral
vector
system
ensur
produc
vector
contamin
wildtyp
viru
adenovir
system
two
homolog
recombin
event
must
occur
restor
wildtyp
viru
render
event
highli
unlik
adenoviru
vector
strongli
induc
innat
arm
immun
system
result
inflamm
infect
tissu
effici
clearanc
administ
vector
muruv
adenoviru
vector
vaccin
develop
varieti
differ
infecti
diseas
enter
clinic
trial
malaria
phase
fitzgerald
et
al
differ
cancer
other
malign
cr
health
net
viruslik
particl
vlp
also
consid
vector
vaccin
despit
nonliv
empti
viral
particl
socal
pseudovirus
noninfecti
lack
viral
genet
inform
normal
packag
particl
techniqu
capac
viral
structur
protein
envelop
capsid
selfassembl
vlp
exploit
kirnbauer
et
al
kost
condreay
valenzuela
et
al
vlp
hbsag
deriv
hbv
alreadi
describ
year
ago
infect
patient
sera
bayer
et
al
nowaday
vlp
produc
licens
hpv
vaccin
addit
whole
varieti
viru
famili
includ
parvovirida
eg
adenoassoci
viru
retrovirida
eg
hiv
polyomavirida
eg
jc
viru
chang
et
al
paramyxovirida
eg
nipah
viru
walpita
et
al
flavivirida
eg
hepat
c
viru
despit
limit
immun
stimulatori
capac
vlp
attract
vaccin
candid
due
higher
safeti
level
compar
lav
fig
vlp
produc
differ
cell
cultur
system
includ
mammalian
rodent
cell
line
insect
cell
line
yeast
also
plant
cell
santi
et
al
vlp
vaccin
foreign
antigen
normal
fuse
viral
envelop
protein
membran
domain
guid
anchor
antigen
surfac
viral
particl
vlp
present
antigen
immun
system
natur
length
nativ
structur
particul
natur
vaccin
promot
immun
recognit
heterolog
antigen
bach
et
al
hunter
et
al
li
et
al
nikl
et
al
walpita
et
al
today
differ
antigen
test
capac
induc
protect
immun
break
immunolog
toler
thu
far
vlpbase
vector
vaccin
enter
clinic
test
phase
new
vaccin
approach
hiv
develop
macaqu
aid
model
use
pathogen
diseaseinduc
agent
vaccin
rhesu
cytomegaloviru
rhcmv
replic
compet
persist
normal
harmless
viru
equip
set
siv
antigen
vaccin
shown
complet
control
siv
infect
spread
infect
anim
normal
achiev
common
strategi
highli
immun
activ
replic
incompet
viral
vector
continu
antigen
deliveri
rhcmvsiv
vaccin
combin
abil
stimul
effector
memori
tcell
respons
suggest
reason
vaccin
success
hansen
et
al
vector
system
might
provid
new
way
develop
effect
hiv
vaccin
last
centuri
clinic
observ
report
cancer
regress
coincid
viru
infect
howev
tumor
regress
mostli
transient
incomplet
kelli
russel
sinkov
horvath
time
knowledg
viru
infect
immun
respons
correl
tumor
regress
therefor
use
oncolyt
virus
today
demand
investig
paramet
reoviru
vaccinia
measl
adeno
herp
vesicular
stomat
viru
well
newcastl
diseas
viru
virus
mainli
consid
therapi
cancer
oncolysi
first
approv
oncolyt
viru
approv
china
europ
usa
kirn
adenoviru
variant
improv
safeti
ie
tumorspecif
infect
replic
well
efficaci
ie
destruct
tumor
eventu
also
metastas
essenti
understand
viral
tropism
host
restrict
addit
influenc
molecular
phenotyp
tumor
techniqu
specif
modifi
virus
ration
design
develop
safe
effici
oncolyt
virus
alreadi
avail
instanc
retarget
modif
viral
envelop
protein
substitut
well
activ
restrict
viral
replic
specif
viral
gene
delet
necessari
gener
safe
tumorspecif
virus
addit
arm
shield
oncolyt
virus
improv
oncolyt
efficaci
arm
refer
equip
viru
gene
encod
prodrugconvert
enzym
immun
stimulatori
protein
enhanc
antitumor
activ
shield
done
chemic
biolog
use
differ
viral
serotyp
prevent
neutral
preexist
virusspecif
antibodi
cattaneo
et
al
recent
report
indic
synergist
effect
direct
viral
oncolysi
activ
specif
antitumor
immun
respons
suggest
inclus
immunotherapeut
approach
viral
antitumor
therapi
boisgerault
et
al
among
variou
immunomodulatori
protein
propos
success
employ
immunestimul
factor
advanc
oncolyt
virus
granulocytemacrophag
colonystimul
factor
gmcsf
second
molecul
although
recombin
virus
harbor
correspond
gene
enter
clinic
trial
yet
melcher
et
al
besid
proteas
glycosidas
strategi
target
angiogenesi
also
test
respect
antitumor
activ
boisgerault
et
al
studi
safeti
efficaci
new
vaccin
candid
preclin
evalu
anim
preced
case
test
human
variou
mous
model
often
use
establish
first
proof
concept
new
vaccin
vivo
regard
safeti
efficaci
sinc
interact
differ
mous
human
care
select
pathogen
challeng
experi
appropri
mous
strain
altern
anim
model
necessari
order
obtain
relev
data
exampl
case
efficaci
test
poxviru
vaccin
common
challeng
model
use
labadapt
vacv
strain
western
reserv
mice
even
though
special
safeti
equip
demand
work
ectromelia
viru
howev
natur
mous
pathogen
caus
mousepox
viru
resembl
much
cours
diseas
progress
variola
viru
human
western
reserv
strain
defin
best
rout
challeng
viru
administr
also
import
besid
footpad
inocul
intranas
infect
appear
mimic
natur
rout
poxviru
infect
thu
model
repres
optim
small
anim
model
studi
mva
orthopoxviru
immunogen
vaccin
success
paran
et
al
paran
sutter
virus
eg
hiv
measl
viru
ebola
viru
infect
replic
mice
due
strict
host
specif
virus
target
anim
monkey
need
case
hiv
infect
macaqu
simian
immunodefici
viru
siv
still
import
anim
model
understand
hiv
pathogenesi
develop
novel
hiv
vaccin
natur
siv
variant
defect
nef
gene
function
found
induc
protect
immun
siv
challeng
thu
provid
valid
tool
studi
immun
paramet
confer
protect
challeng
viru
daniel
et
al
howev
due
ethic
concern
high
cost
low
number
anim
use
experiment
set
altern
attempt
made
develop
new
mous
strain
transgen
human
compon
exampl
mous
transgen
human
slam
receptor
enabl
measl
viru
infect
replic
otherwis
resist
mice
ohno
et
al
addit
immunogen
paramet
would
also
repres
human
alway
found
anim
model
therefor
socal
human
mice
develop
lack
part
immun
system
thu
reconstitut
human
hematopoiet
stem
cell
function
human
immun
cell
develop
legrand
et
al
similarli
human
mice
success
test
infect
experi
use
typhi
bacteri
pathogen
exclus
restrict
human
song
et
al
although
procedur
human
mice
experiment
still
challeng
reason
expect
system
introduc
test
vaccin
therapeut
intend
human
use
use
lav
made
indispens
contribut
fight
infecti
diseas
initi
undirect
mutagenesi
extend
passag
employ
render
vaccin
safe
today
modern
molecular
genet
allow
ration
design
live
microb
effici
safer
vaccin
vector
system
deliveri
heterolog
prophylact
therapeut
macromolecul
number
bacteri
viral
case
eukaryot
vector
system
consid
prospect
carrier
protein
nucleic
acid
polysaccharid
cargo
addit
vaccin
live
vector
offer
new
rout
treatment
variou
disord
cancer
gene
defici
allergi
autoimmun
diseas
howev
introduct
new
gener
recombin
live
vector
system
medic
practic
long
endeavor
order
meet
requir
approv
safe
efficaci
control
use
system
care
demonstr
preclin
clinic
addit
risk
associ
genet
modifi
lav
might
releas
environ
comprehens
assess
recent
introduct
sever
recombin
bacteri
viral
lav
practic
valuabl
proof
concept
help
pave
road
develop
vaccin
futur
